Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study

Dicken Kong, Jiandong Zhou, Sharen Lee, Keith Sai Kit Leung, Tong Liu, Abhishek C Sawant, John Corbelli, Abraham KC Wai, Carlin Chang, View ORCID ProfileQingpeng Zhang, Gary Tse
doi: https://doi.org/10.1101/2021.01.04.21249209
Dicken Kong
1Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Li Ka Shing Institute of Health Sciences and Chinese University Research Institute, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiandong Zhou
2School of Data Science, City University of Hong Kong, Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharen Lee
3Aston Medical School, Aston University, Birmingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Sai Kit Leung
1Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Li Ka Shing Institute of Health Sciences and Chinese University Research Institute, China
3Aston Medical School, Aston University, Birmingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tong Liu
4Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abhishek C Sawant
5Banner University Medical Center, Phoenix, Arizona, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Corbelli
6Western New York Healthcare System, Buffalo VA Medical Center, Buffalo, New York, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abraham KC Wai
7Emergency Medicine Unit, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlin Chang
8Division of Neurology, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingpeng Zhang
1Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Li Ka Shing Institute of Health Sciences and Chinese University Research Institute, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qingpeng Zhang
  • For correspondence: qingpeng.zhang@cityu.edu.hk gary.tse@doctors.org.uk
Gary Tse
4Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: qingpeng.zhang@cityu.edu.hk gary.tse@doctors.org.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background In this territory-wide, observational, propensity score-matched cohort study, we evaluate the development of transient ischaemic attack and ischaemic stroke (TIA/Ischaemic stroke) in patients with AF treated with edoxaban or warfarin.

Methods This was an observational, territory-wide cohort study of patients between January 1st, 2016 and December 31st, 2019, in Hong Kong. The inclusion were patients with i) atrial fibrillation, and ii) edoxaban or warfarin prescription. 1:2 propensity score matching was performed between edoxaban and warfarin users. Univariate Cox regression identifies significant risk predictors of the primary, secondary and safety outcomes. Hazard ratios (HRs) with corresponding 95% confidence interval [CI] and p values were reported.

Results This cohort included 3464 patients (54.18% males, median baseline age: 72 years old, IQR: 63-80, max: 100 years old), 664 (19.17%) with edoxaban use and 2800 (80.83%) with warfarin use. After a median follow-up of 606 days (IQR: 306-1044, max: 1520 days), 91(incidence rate: 2.62%) developed TIA/ischaemic stroke: 1.51% (10/664) in the edoxaban group and 2.89% (81/2800) in the warfarin group. Edoxaban was associated with a lower risk of TIA or ischemic stroke when compared to warfarin.

Conclusions Edoxaban use was associated with a lower risk of TIA or ischemic stroke after propensity score matching for demographics, comorbidities and medication use.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee and Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Joint first authors

Data Availability

Data available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study
Dicken Kong, Jiandong Zhou, Sharen Lee, Keith Sai Kit Leung, Tong Liu, Abhishek C Sawant, John Corbelli, Abraham KC Wai, Carlin Chang, Qingpeng Zhang, Gary Tse
medRxiv 2021.01.04.21249209; doi: https://doi.org/10.1101/2021.01.04.21249209
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study
Dicken Kong, Jiandong Zhou, Sharen Lee, Keith Sai Kit Leung, Tong Liu, Abhishek C Sawant, John Corbelli, Abraham KC Wai, Carlin Chang, Qingpeng Zhang, Gary Tse
medRxiv 2021.01.04.21249209; doi: https://doi.org/10.1101/2021.01.04.21249209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5214)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (749)
  • Geriatric Medicine (76)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (222)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5814)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (853)
  • Public and Global Health (1992)
  • Radiology and Imaging (343)
  • Rehabilitation Medicine and Physical Therapy (156)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)